Clinical Trials

60 enrolled

Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

50 enrolled

Breast Neoplasms

NCT07340398 2026-01-21

TAYLOR

200 enrolled

HER2-positive Early Breast Cancer

NCT05910398 2025-11-18

CORINNE-PI

488 enrolled

Breast Cancer Invasive

NCT07180082 2025-11-18

CORIN-PYRA

186 enrolled

Advanced Breast Cancer

NCT04254263 2025-09-11

ATP

316 enrolled

Locally Advanced Breast Cancer

NCT05582499 2025-08-22

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

74 enrolled

Breast Neoplasms

NCT06958627 2025-05-06

any

Phase 2/3 Recruiting

964 enrolled

HER2 Positive Breast Cancer

NCT06035679 2025-03-12

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

Phase NA Recruiting

30 enrolled

Breast Cancer Female

NCT06832904 2025-02-18

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

33 enrolled

HER2-positive Breast Cancer

NCT06718933 2025-02-06

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

Phase 1/2 Recruiting

74 enrolled

Breast Cancer Metastatic

NCT06770296 2025-01-13

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

Phase 1 Recruiting

200 enrolled

Breast Neoplasms

NCT06754059 2025-01-01

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

Recruiting

60 enrolled

HER2-positive Breast Cancer

NCT05635487 2024-07-05

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

65 enrolled

HER2-positive Breast Cancer

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

65 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05861271 2024-03-22

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

1,008 enrolled

Breast Neoplasms

NCT06217185 2024-02-28

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Phase 4 Recruiting

100 enrolled

HER2-positive Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

312 enrolled

HER2-positive Metastatic Breast Cancer

NCT06234137 2024-01-31

neoPICD

Phase NA Recruiting

154 enrolled

Breast Neoplasm Female

NCT06000917 2023-08-21

A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

62 enrolled

Breast Neoplasms

NCT05856383 2023-05-12

HER2-VIP

Recruiting

100 enrolled

HER2-positive Advanced Breast Cancer

NCT05834764 2023-04-28

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

188 enrolled

HER2-positive Breast Cancer

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

236 enrolled

Breast Neoplasms

NCT04646759 2020-11-30

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

516 enrolled

Breast Neoplasms

NCT04481932 2020-07-22

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

104 enrolled